Literature DB >> 2868747

Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol.

W H Aellig, E Nüesch, G Engel, J Grevel, W Niederberger, J Rosenthaler.   

Abstract

Bopindolol, an esterified beta-adrenoceptor blocking drug, was administered to nine healthy male volunteers in oral (1 mg and 4 mg) and intravenous (1 mg) doses. Plasma concentrations determined using a radio-receptor assay (RRA) and high pressure liquid chromatography (h.p.l.c.) yielded almost identical results, indicating that hydrolysed bopindolol, the major metabolite, is responsible for the pharmacological activity of the drug. After intravenous administration the half-life for the formation of the hydrolysis product was about 0.3 h. The elimination of hydrolysed bopindolol from the plasma, determined with a one-compartment model occurred with a half-life of about 4 h. There were indications for a longer beta phase of elimination with a half-life of about 8 h, which, owing to the relative insensitivity of the method for concentrations present after more than 24 h, could not be determined exactly. The absolute bioavailability of the active compound is about 70%. Cardiac beta-adrenoceptor blockade was determined as the reduction in exercise-induced tachycardia. With oral doses the maximum effect was reached after 3 h (-29 beats min-1 after 1 mg, -40 beats min-1 after 4 mg). After intravenous administration most of the effect was present after 0.5 h but the maximum effect (-33 beats min-1) was only reached at 3 h. Bopindolol possesses a long duration of action: after 48 h 33% of the maximum effect of the oral dose of 4 mg was still present.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2868747      PMCID: PMC1400800          DOI: 10.1111/j.1365-2125.1986.tb02821.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Solubilization of a mammalian beta-adrenergic receptor.

Authors:  J Kleinstein; H Glossmann; L Braun; C Konrad
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-12       Impact factor: 3.000

2.  Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate.

Authors:  S G Carruthers; J G Kelly; D G McDevitt; R G Shanks
Journal:  Clin Pharmacol Ther       Date:  1974-05       Impact factor: 6.875

3.  Duration of action and plasma levels of beta-adrenoceptor blocking drugs.

Authors:  W H Aellig
Journal:  Arch Int Pharmacodyn Ther       Date:  1980

4.  An investigation of the relationship between beta-adrenoceptor blockade and plasma practolol concentration in man.

Authors:  C R Kumana; C M Kaye
Journal:  Eur J Clin Pharmacol       Date:  1974-07-26       Impact factor: 2.953

5.  Pharmacological experiments in healthy volunteers with bopindolol, a long-acting beta-adrenoceptor blocking drug with partial agonist activity.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

6.  Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man.

Authors:  D J Coltart; D G Shand
Journal:  Br Med J       Date:  1970-09-26

7.  (+/-)[125Iodo] cyanopindolol, a new ligand for beta-adrenoceptors: identification and quantitation of subclasses of beta-adrenoceptors in guinea pig.

Authors:  G Engel; D Hoyer; R Berthold; H Wagner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981       Impact factor: 3.000

8.  Simultaneous modeling of bopindolol kinetics and dynamics.

Authors:  R Platzer; R L Galeazzi; W Niederberger; J Rosenthaler
Journal:  Clin Pharmacol Ther       Date:  1984-07       Impact factor: 6.875

9.  Evaluation of a radioreceptor assay for beta-adrenoceptor antagonists in plasma.

Authors:  D B Barnett; M Batta; B Davies; S R Nahorski
Journal:  Eur J Clin Pharmacol       Date:  1980-05       Impact factor: 2.953

  9 in total
  6 in total

1.  Steady state pharmacokinetics of hydrolysed bopindolol in young and elderly men.

Authors:  D Holmes; E Nuesch; J M Houle; J Rosenthaler
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Comparison of the acute haemodynamic effects of bopindolol and propranolol at rest and during supine exercise.

Authors:  P Fitscha; W Meisner; B Tiso
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  The effect of renal impairment on the pharmacokinetics and metabolism of bopindolol.

Authors:  N J MacDonald; A C Grant; R S Rodger; P A Meredith; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

Review 4.  Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.

Authors:  D W Harron; K L Goa; H D Langtry
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

5.  Pharmacokinetics after a single oral dose of bopindolol in patients with cirrhosis.

Authors:  G Wensing; R A Branch; H Humbert; E E Ohnhaus; W Kirch
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.